MedRhythms Hires Joel Behnke as Chief Commercial Officer; Announces New Publications in Support of InTandem® [Yahoo! Finance]
Bioventus Inc. - Class A (BVS)
Company Research
Source: Yahoo! Finance
Tue, February 4, 2025 at 2:00 PM GMT+1 4 min read PORTLAND, Maine Feb. 4, 2025 /PRNewswire/ -- MedRhythms, Inc. today announced that Joel Behnke has been hired as Chief Commercial Officer. Mr. Behnke brings over two decades of commercial leadership in medical devices to MedRhythms where he will drive sales and marketing efforts across the pipeline of products, with initial focus on commercialization of InTandem, the company's flagship neurorehabilitation system for chronic stroke gait impairment. (PRNewsfoto/MedRhythms) "Mr. Behnke is a highly respected and high caliber executive," said Brian Harris , MedRhythms' Co-Founder and CEO. "Joel has a strong track record of demonstrated success in scaling medical devices in rehabilitation, s
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Bioventus Inc. (NYSE: BVS) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $15.00 price target on the stock.MarketBeat
- Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Bioventus Non-GAAP EPS of $0.15 beats by $0.07, revenue of $153.64M beats by $8.48M [Seeking Alpha]Seeking Alpha
- Bioventus Announces Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire
- Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025GlobeNewswire
BVS
Earnings
- 3/11/25 - Beat
BVS
Analyst Actions
- 3/17/25 - Canaccord Genuity
BVS
Sec Filings
- 3/25/25 - Form 4
- 3/24/25 - Form 144
- 3/21/25 - Form 4
- BVS's page on the SEC website